# Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

> **NCT00750282** · PHASE2 · COMPLETED · sponsor: **Life Molecular Imaging SA** · enrollment: 422 (actual)

## Conditions studied

- Alzheimer Disease
- Amyloid Beta-Protein

## Interventions

- **DRUG:** Florbetaben (BAY94-9172)

## Key facts

- **NCT ID:** NCT00750282
- **Lead sponsor:** Life Molecular Imaging SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2014-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750282, "Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00750282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*